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DOI: http://dx.doi.org/10.1016/j.hemonc.2014.06.002BACKGROUND: Non-invasive methods like MRI-based techniques have been considered recently for assess-
ment of liver and heart status in patients with thalassemia major (TM). The purpose of this study is to examine the
alterations of hepatic and myocardial T2* MRI values in TM patients after hematopoietic stem cell transplanta-
tion (HSCT) just before starting chelation therapy.
PROCEDURE: The study included fifty-two TM patients with mean age of 7.6 years who were referred to our
center for HSCT. Before HSCT, patients underwent liver biopsy to determine fibrosis stage based on the Lucarelli
classification. Hepatic and myocardial T2* values before and 6 months after transplantation were measured and
analyzed.
RESULTS: There was not a statistically significant increase in myocardial T2* values after HSCT
(p-value = 0.35). Hepatic T2* values significantly decreased after HSCT (p-value <0.001), showing the liver
status has been worsened. In subgroup analysis, post-HSCT hepatic T2* values (adjusted for baseline values)
were significantly higher in patients with graft-versus-host disease (GvHD) compared to non-GvHD patients
(p-value = 0.04).
CONCLUSIONS: The issue of iron overload is still remained as the main problem in ex-thalassemic patients
after HSCT. We found T2* MRI technique a quite beneficial method for following up the patients after transplan-
tation. Obviously, planning large controlled trials associated with liver biopsy results after transplantation is
required.
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prevalent hematologic inherited disorders.1,2
Nowadays, considering the high probability of
event-free survival (80%) reported for HSCT,3 it
has been settled as the only curative treatment for
TM patients.4 The aim of treatment with HSCT is
to rectify the ineffective endogenous erythropoiesis
with allogenic substitute.3 One of the main problems
for ex-thalassemic patients after transplantation is
excessive iron overload which may results in different
tissue injuries in future mainly in the heart andliver.5–12 On the other hand, this iron overload has
probably affected many outcomes which graft-
versus-host disease (GvHD) occurrence is one of
them. While some articles expressed that iron
overload raises the rate of graft-versus-host disease
(GvHD) occurrence in ex-thalassemic patients,5,6 it
has been recently showed that iron overload can
reduce the incidence of GvHD7 by its immunosup-
pressive effect.8–12 Although non-invasive methods
like measuring serum ferritin level has been utilized
as a detector for iron overload, ferritin values can be
easily inﬂuenced by simple events such as inﬂamma-
tion and infections.13 It is worthy to mention that103
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liver biopsy is not desired after a successful transplan-
tation because of being invasive, inconvenience and
having complications. On the other hand, it should
not be neglected that cardiac biopsy is completely
dangerous and impossible. All the above discussed
reasons resulted in utilizing MRI-based methods14–17
in which T2* MRI technique has earned more
attention than the other methods because of its high
efﬁciency in estimation of iron overload either in the
heart or liver.18–21 However, there are few studies
investigating the application of MRI-based methods
for assessment of iron overload post-HSCT.22,23
This study attempted to investigate the status of
iron overload in the heart and liver in ex-thalassemic
patients, using noninvasive method after HSCT and
immediately before starting chelation therapy. In this
study, we aimed to ﬁnd answers to the following ques-
tions: Is the situation getting worse or better? What is
the role of GvHD on this state?PATIENTS AND METHODS
Patient characteristics
The target population was HSCT candidates with
TM (aged < 15) who were referred to the Hematol-
ogy-Oncology Research Center and Stem Cell Trans-
plantation (HORCSCT) from March 2009 to April
2012. The Institutional Review Board and Ethics
Committee approved the study protocol which was
in accordance with the principles of the Declaration
of Helsinki. The parents of children with TM signed
an informed consent to participate in the study based
on the exclusion and inclusion criteria. The diagnosis
of TM had already been conﬁrmed in the referral
medical centers by hemoglobin electrophoresis or
mutation analysis. Patients with cardiac disease,
AIDS, HBV, HCV or progressive cirrhosis were
excluded from the study. It is worthy to mention that
all patients underwent echocardiography and EKG.
Moreover, a cardiac consultation was arranged before
transplantation. For categorizing the patients and
determination of Lucarelli classiﬁcation, liver biopsy
samples were taken from all patients. No patient
underwent liver biopsy after HSCT due to invasive-
ness and intolerability. Regarding the iron overload
in the heart and liver, T2* MRI values and serum fer-
ritin level were measured in all patients before HSCT
and 6 months after transplantation just before starting
iron chelation therapy.
Transplant preparation and procedure
Patients and their relatives were checked to ﬁnd
HLA-A, HLA-B, and HLA-DR matched donors byHemlow-resolution molecular typing. The sources of pro-
genitors were peripheral blood stem cell (PBSC),
bone marrow stem cell (BMSC), or cord blood. Mar-
row was harvested from iliac crests when the donor
was under general anesthesia and directly infused into
the recipients without further manipulation. The
peripheral blood stem cells were mobilized by
granulocyte colony-stimulating factor (G-CSF), using
5 lg/kg for 4 days.
Conditioning regimens and GvHD prophylaxis
The conditioning regimens in class I-II thalassemia
patients included busulfan (3.5 mg/kg/day from day
8 for four consecutive days), cyclophosphamide
(50 mg/kg/day IV from day 4 for four
consecutive days) and rabbit antithymocyte globulin
(Thymoglobin, 1.25 mg/kg IV two consecutive days
before transplantation). All class III patients with
thalassemia received conditioning regimen of
busulfan (3.5 mg/kg/day from day 9 for four
consecutive days) and cyclophosphamide
(40 mg/kg/day IV from day 5 for four consecu-
tive days).
Regarding GvHD prophylaxis, cyclosporine
(1.5 mg/kg daily, IV, on day 2, and then 3 mg/kg
on day +7) in combination with a short-course treat-
ment with methotrexate (10 mg/m2 on days +1 and
6 mg/m2 on days +3,+6, and +11) was administered
for patients. Cyclosporine continued orally for
6–7 months after HSCT and discontinued in the
absence of GvHD.
Supportive care
Regarding supportive care, all the patients were hospi-
talized in protective isolation with hyperalimentation.
Acyclovir and ﬂuconazole were given as prophylaxis
for the prevention of viral or fungal infections and tri-
methoprim–sulfamethoxazole was administrated to
prevent Pneumocystis jiroveci. To check CMV infec-
tions, quantitative PCR or CMV PP65 antigen assay
was performed twice weekly. All patients received
phenytoin as prophylaxis for busulfan- induced
seizures.
Follow-up
Based on Short Tandem Repeat (STR) typing,
hematopoietic chimerism monitoring was performed
on days 15, 30, 60, 90, and 180 after HSCT. After
discharge, all patients were followed up in the
post- HSCT clinic weekly during the ﬁrst month,
then every 2 weeks by day 100 after HSCT, and
thereafter it was conducted on an individual case
basis.atol Oncol Stem Cell Ther 7(3) Third Quarter 2014 hemoncstem.edmgr.com
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Acute and chronic GvHD were evaluated and graded
on the basis of standard criteria.24,25 Neutrophil
engraftment was deﬁned as the achievement of periph-
eral granulocyte count more than 500 · 103/ml for 3
consecutive days without G-CSF administration and
platelet count more than 20,000 · 103/ml for 7 con-
secutive days in the absence of transfusion support.
T2* MRI technique
All the patients were evaluated by T2* MRI to assess
iron overload in the liver and heart before HSCT and
6 months after transplantation. 1.5 Tesla Magnetom
Siemens Symphony scanner (Siemens Medical Solu-
tion, Erlangen, Germany), was used as a standard
quadrature radiofrequency body coil in all measure-
ments. To determine T2* values, the Royal Brompton
protocol on the basis of fast gradient echo sequences
and single-breath hold was used. Motion-related arti-
facts were eliminated by spatial presaturation slabs.
All the patients were placed in a supine position
and entered the magnet cradle, using the head-ﬁrst
conﬁguration. A 10 mm slide thickness in liver core
scanned at twelve different echo times (TE 1.3–23 ms)
was used for calculation of hepatic T2 values.
Each image was taken within 11–13 s of breath hold-
ing using gradient echo sequence (repetition time
200 ms, ﬂip angle 20, base resolution matrix 128 pix-
els, ﬁeld of view 39.7 cm · 19.7 cm, sampling band-
width 125 kHz). The background noise and plotted
the net value against the echo time in all images was
subtracted. To derive T2*, an exponential trend-line
is ﬁtted with an equation in the form y = KeTE/T2*
where K represents a constant, TE represents the
echo time and y represents the image signal intensity.
T2* values were calculated using a software (CMR
tools, Imperial College). Liver and myocardial scans
took 10–15 min and (electrocardiographic) ECG gat-
ing was used in cardiac imaging. A homogeneous full-
thickness region of interest (ROI) was outlined in the
ventricular septum. The mean signal intensity of
region was computed for each image and plotted
against the echo time (TE).RESULTS
52 out of 55 patients enrolled in the study were alive
and disease-free after 6 months. They all showed full
chimerism and became non-transfusion dependent.
Of 52 patients, 29 boys and 23 girls with mean age
of 7.6 years (range: 2–14), the number of patients with
thalassemia class II based on Lucarelli ClassiﬁcationHematol Oncol Stem Cell Ther 7(3) Third Quarter 2014 hemoncstem.edmgr.comwas greater than the two other classes. Other patients’
characteristics are illustrated in Table 1.
Pre-HSCT analysis showed that there was no sig-
niﬁcant correlation between myocardial T2* values
and hepatic T2* values (Spearman’s Rho = 0.006,
p-value = 0.97).
Although myocardial T2* values were higher after
HSCT, no signiﬁcant difference was observed in T2*
values between pre and post-HSCT (p-value = 0.35),
showing iron overload has decreased insigniﬁcantly in
the heart. However, hepatic T2* values were signiﬁ-
cantly decreased after HSCT (p-value <0.001), show-
ing liver iron concentration has increased signiﬁcantly
after HSCT. This outcome was conﬁrmed by com-
parison of serum ferritin status before and after
HSCT which showed that ferritin level was markedly
increased after HSCT (p-value <0.001). In subgroup
analysis, these results were found to be different in
GvHD status.
Hepatic T2* values were decreased signiﬁcantly
in GvHD and non-GvHD patients after HSCT
(p-value = 0.05, 0.001, respectively). Compared with
non-GvHD patients, post-HSCT hepatic T2* values
(adjusted for baseline values) were signiﬁcantly higher
in patients with GvHD (p-value = 0.04), showing
liver iron overload has been worsened in non-GvHD
patients (Fig. 1).
There was no signiﬁcant difference between
GvHD and non-GvHD patients in ferritin values
(p-value = 0.50) (Fig. 2) although ferritin values were
increased signiﬁcantly after HSCT in patients with
GvHD (p-value <0.001). No statistically signiﬁcant
increase in serum ferritin level was observed in non-
GvHD patients after HSCT (p-value = 0.07).DISCUSSION
Approximately 80% of TM patients who receive
hematopoietic stem cell transplant will be cured,3
but their follow-up status is completely much more
different than that of the patients with other types
of diseases such as leukemia. Because, in addition to
common complications, they suffer excessive iron
overload caused by multiple times of blood transfu-
sion, resulting in the incidence of serious complica-
tions for heart and liver in future that actually will
lower the quality of their lives. Evaluation of iron
overload is widely investigated by various methods
and devices all over the world. liver biopsy is currently
the gold standard for evaluation of liver iron overload,
but it is always accompanied by its own problems
including inconvenience for serial observations,105
Table 1. Characteristics of TM patients.
Sex
Male 29 (55.8%)
Female 23 (44.2%)
Age (years) 7.6 € 3.1 (2–14)
Thalassemia classification
Class I 10 (19.2%)
Class II 33 (63.5%)
Class III 9 (17.3%)
Source of progenitor
PBSC 39 (75.0%)
Bone marrow 12 (23.1%)
Cord blood 1 (1.9%)
Donor age (years) 15.2 € 10.8 (0–60)
Donor recipient sex
Male to male 18 (34.6%)
Male to female 15 (28.8%)
Female to male 11 (21.2%)
Female to female 8 (15.4%)
Donor relation
Siblings 43 (82.7%)
Other 9 (17.3%)
RBC Pack cells during hospitalization 5.33 € 2.25
Duration of hospitalization (days) 32.18 € 7.51
T2 Heart before HSCT (ms) 18.91 € 7.19
T2 Liver before HSCT (ms) 4.21 € 3.34
T2 Heart after HSCT (ms) 19.9 € 7.71
T2 Liver after HSCT (ms) 3.17 € 2.05
Ferritin before HSCT (ng/ml) 2232 € 1891
Ferritin after HSCT (ng/ml) 3772 € 2497
Ejection fraction (%) 65 € 11
Acute GvHD
No aGvHD 26 (50%)
I 7 (13.5%)
II 7 (13.5%)
Table 1. (Continued)
Sex
III 4 (7.7%)
IV 8 (15.4%)
Chronic GvHD
No cGvHD 47 (90.4%)
Limited 3 (5.8%)
Extensive 2 (3.8%)
Neutrophil recovery up to 500/ll(days) 12 € 2
Platelet recovery up to 20,000/ll(days) 19 € 5
*MNC (·108/ml) 6.7 € 2.18
CD34 (·106/ml) 4.4 € 2.7
MNC: mononuclear cells.
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live volume, inter- and intra- observer variability and
sampling errors.26–28 Note that the cardiac biopsy is
completely dangerous and unfavorable. On the other
hand, using other methods like echocardiography
and ECG could not help us efﬁciently to determine
the iron overload in the heart. Detection of iron over-
load is currently performed by measuring serum ferri-
tin level which is unreliable because of being affected
by various factors.13 Applying non-invasive methods
such as MRI technique, especially T2* MRI, has been
investigated.14–17
To the best of our knowledge, only one study in
Athens, in which the patients were given chelation
therapy, showed the liver and heart status in 8 ex-thal-
assemic patients after HSCT, using T2* MRI
technique.23
In the present study, T2* values showed worsening
liver iron overload after transplantation, meaning that
multiple blood transfusions can cause deterioration of
iron overload in these patients during transplantation.
This is why it is important to check the iron overload
in ex-thalassemic patients just before starting chela-
tion therapy.
In subgroup analysis, regarding GvHD occurrence,
the results were interesting. Based on the comparison
between two tests (Figs. 1 and 2), T2* values showed
that liver iron overload was getting much worse in
non-GvHD patients compared to patients with
GvHD, whereas ferritin level indicated that iron over-
load status was getting much worse in patients with
GvHD. These ﬁndings were completely confusing
because simple events such as inﬂammation can easilyatol Oncol Stem Cell Ther 7(3) Third Quarter 2014 hemoncstem.edmgr.com
Fig. 2. Comparison of ferritin changes in GvHD and no-GvHD group; before and after HSCT.
Fig. 1. Comparison of hepatic T2* MRI changes in GvHD and no-GvHD group; before and after HSCT.
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conclusions. This is why ferritin level is not consid-
ered to be most appropriate in following-up ex-thalas-
semic patients. To answer the question ‘‘Which test is
correctly expressing the truth about liver situation after
HSCT, especially considering GvHD status?’’ we must
compare these results with liver biopsy outcome that
we all know is quite impossible and it is not reason-
able to ask ex-thalassemic patients to undergo liver
biopsy. Due to medical ethics, liver biopsy was not
selected as the preferred option.Hematol Oncol Stem Cell Ther 7(3) Third Quarter 2014 hemoncstem.edmgr.comRegarding myocardial T2 values, although our
results showed no signiﬁcant difference in pre-and
post-transplant iron overload in heart, the level of iron
overload was decreased after HSCT.
In conclusion, we have found that T2* MRI tech-
nique is quite a useful non-invasive method to follow-
up post transplant patients. Although this study did
not show a worsening of cardiac status after HSCT,
liver was found worsening with iron overload that
shows we should consider the ﬁnal liver injury made
by iron overload (like ﬁbrosis) with other non-invasive107
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methods such as elastography. There is still a big
challenge to ﬁnd the best method for evaluation of
iron status in ex-thalassemic patients. However, large
case-control studies accompanied by liver biopsy
results are required.CONFLICT OF INTEREST
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